Harvard Bioscience, Inc.
HBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $94,135 | $112,250 | $113,335 | $118,904 |
| % Growth | -16.1% | -1% | -4.7% | – |
| Cost of Goods Sold | $39,369 | $46,179 | $52,516 | $51,252 |
| Gross Profit | $54,766 | $66,071 | $60,819 | $67,652 |
| % Margin | 58.2% | 58.9% | 53.7% | 56.9% |
| R&D Expenses | $10,406 | $11,764 | $12,329 | $10,799 |
| G&A Expenses | $21,493 | $22,780 | $24,493 | $24,305 |
| SG&A Expenses | $43,705 | $46,888 | $49,534 | $48,947 |
| Sales & Mktg Exp. | $22,212 | $24,108 | $25,041 | $24,642 |
| Other Operating Expenses | $6,866 | $5,525 | $5,889 | $5,840 |
| Operating Expenses | $60,977 | $64,177 | $67,752 | $65,586 |
| Operating Income | -$6,211 | $1,894 | -$6,933 | $2,066 |
| % Margin | -6.6% | 1.7% | -6.1% | 1.7% |
| Other Income/Exp. Net | -$5,454 | -$4,450 | -$2,246 | -$2,206 |
| Pre-Tax Income | -$11,665 | -$2,556 | -$9,179 | -$140 |
| Tax Expense | $740 | $859 | $337 | $148 |
| Net Income | -$12,405 | -$3,415 | -$9,516 | -$288 |
| % Margin | -13.2% | -3% | -8.4% | -0.2% |
| EPS | -0.28 | -0.081 | -0.23 | -0.007 |
| % Growth | -247.8% | 65% | -3,139.4% | – |
| EPS Diluted | -0.28 | -0.081 | -0.23 | -0.007 |
| Weighted Avg Shares Out | 43,538 | 42,420 | 41,413 | 40,343 |
| Weighted Avg Shares Out Dil | 43,538 | 42,420 | 41,413 | 40,343 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3,209 | $3,591 | $2,548 | $1,540 |
| Depreciation & Amortization | $6,982 | $6,998 | $7,575 | $7,621 |
| EBITDA | -$1,474 | $8,033 | $944 | $9,021 |
| % Margin | -1.6% | 7.2% | 0.8% | 7.6% |